Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters

The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host’s protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian h...

Full description

Saved in:
Bibliographic Details
Published inNature microbiology Vol. 7; no. 8; pp. 1252 - 1258
Main Authors Uraki, Ryuta, Kiso, Maki, Imai, Masaki, Yamayoshi, Seiya, Ito, Mutsumi, Fujisaki, Seiichiro, Takashita, Emi, Ujie, Michiko, Furusawa, Yuri, Yasuhara, Atsuhiro, Iwatsuki-Horimoto, Kiyoko, Sakai-Tagawa, Yuko, Watanabe, Shinji, Hasegawa, Hideki, Kawaoka, Yoshihiro
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.08.2022
Nature Publishing Group
Subjects
631/326/596/1296
631/326/596/4130
64
82/1
Antiviral agents
Biomedical and Life Sciences
Coronaviruses
DNA-directed RNA polymerase
Immune response
Infectious Diseases
Life Sciences
Medical Microbiology
Microbiology
Monoclonal antibodies
Parasitology
Proteinase inhibitors
Replication
RNA polymerase
RNA-directed RNA polymerase
Rodents
Severe acute respiratory syndrome coronavirus 2
Spike protein
Virology
Online AccessGet full text

Cover

Abstract The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host’s protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian hamsters. Of the FDA-approved therapeutic mAbs tested (that is, REGN10987/REGN10933, COV2-2196/COV2-2130 and S309), only COV2-2196/COV2-2130 efficiently inhibited BA.1 replication in the lungs of hamsters, and this effect was diminished against a BA.1.1 variant possessing the S-R346K substitution. In addition, treatment of BA.1-infected hamsters with molnupiravir (a SARS-CoV-2 RNA-dependent RNA polymerase inhibitor) or S-217622 (a SARS-CoV-2 protease inhibitor) strongly reduced virus replication in the lungs. These findings suggest that the use of therapeutic mAbs in Omicron-infected patients should be carefully considered due to mutations that affect efficacy, and demonstrate that the antiviral compounds molnupiravir and S-217622 are effective against Omicron BA.1 variants. Therapeutic monoclonal antibodies (COV2-2196/COV2-2130) inhibited the replication of SARS-CoV-2 Omicron BA.1 but not BA.1.1 variants in the lungs of Syrian hamsters. Antivirals (molnupiravir and S-217622) were effective against BA.1 in hamsters.
AbstractList The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host's protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian hamsters. Of the FDA-approved therapeutic mAbs tested (that is, REGN10987/REGN10933, COV2-2196/COV2-2130 and S309), only COV2-2196/COV2-2130 efficiently inhibited BA.1 replication in the lungs of hamsters, and this effect was diminished against a BA.1.1 variant possessing the S-R346K substitution. In addition, treatment of BA.1-infected hamsters with molnupiravir (a SARS-CoV-2 RNA-dependent RNA polymerase inhibitor) or S-217622 (a SARS-CoV-2 protease inhibitor) strongly reduced virus replication in the lungs. These findings suggest that the use of therapeutic mAbs in Omicron-infected patients should be carefully considered due to mutations that affect efficacy, and demonstrate that the antiviral compounds molnupiravir and S-217622 are effective against Omicron BA.1 variants.The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host's protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian hamsters. Of the FDA-approved therapeutic mAbs tested (that is, REGN10987/REGN10933, COV2-2196/COV2-2130 and S309), only COV2-2196/COV2-2130 efficiently inhibited BA.1 replication in the lungs of hamsters, and this effect was diminished against a BA.1.1 variant possessing the S-R346K substitution. In addition, treatment of BA.1-infected hamsters with molnupiravir (a SARS-CoV-2 RNA-dependent RNA polymerase inhibitor) or S-217622 (a SARS-CoV-2 protease inhibitor) strongly reduced virus replication in the lungs. These findings suggest that the use of therapeutic mAbs in Omicron-infected patients should be carefully considered due to mutations that affect efficacy, and demonstrate that the antiviral compounds molnupiravir and S-217622 are effective against Omicron BA.1 variants.
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host’s protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian hamsters. Of the FDA-approved therapeutic mAbs tested (that is, REGN10987/REGN10933, COV2-2196/COV2-2130 and S309), only COV2-2196/COV2-2130 efficiently inhibited BA.1 replication in the lungs of hamsters, and this effect was diminished against a BA.1.1 variant possessing the S-R346K substitution. In addition, treatment of BA.1-infected hamsters with molnupiravir (a SARS-CoV-2 RNA-dependent RNA polymerase inhibitor) or S-217622 (a SARS-CoV-2 protease inhibitor) strongly reduced virus replication in the lungs. These findings suggest that the use of therapeutic mAbs in Omicron-infected patients should be carefully considered due to mutations that affect efficacy, and demonstrate that the antiviral compounds molnupiravir and S-217622 are effective against Omicron BA.1 variants. Therapeutic monoclonal antibodies (COV2-2196/COV2-2130) inhibited the replication of SARS-CoV-2 Omicron BA.1 but not BA.1.1 variants in the lungs of Syrian hamsters. Antivirals (molnupiravir and S-217622) were effective against BA.1 in hamsters.
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host's protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian hamsters. Of the FDA-approved therapeutic mAbs tested (that is, REGN10987/REGN10933, COV2-2196/COV2-2130 and S309), only COV2-2196/COV2-2130 efficiently inhibited BA.1 replication in the lungs of hamsters, and this effect was diminished against a BA.1.1 variant possessing the S-R346K substitution. In addition, treatment of BA.1-infected hamsters with molnupiravir (a SARS-CoV-2 RNA-dependent RNA polymerase inhibitor) or S-217622 (a SARS-CoV-2 protease inhibitor) strongly reduced virus replication in the lungs. These findings suggest that the use of therapeutic mAbs in Omicron-infected patients should be carefully considered due to mutations that affect efficacy, and demonstrate that the antiviral compounds molnupiravir and S-217622 are effective against Omicron BA.1 variants.
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host’s protective immune response. Here we assessed the efficacy of therapeutic monoclonal antibodies (mAbs) against Omicron variant (B.1.1.529) sublineage BA.1 variants in Syrian hamsters. Of the FDA-approved therapeutic mAbs tested (that is, REGN10987/REGN10933, COV2-2196/COV2-2130 and S309), only COV2-2196/COV2-2130 efficiently inhibited BA.1 replication in the lungs of hamsters, and this effect was diminished against a BA.1.1 variant possessing the S-R346K substitution. In addition, treatment of BA.1-infected hamsters with molnupiravir (a SARS-CoV-2 RNA-dependent RNA polymerase inhibitor) or S-217622 (a SARS-CoV-2 protease inhibitor) strongly reduced virus replication in the lungs. These findings suggest that the use of therapeutic mAbs in Omicron-infected patients should be carefully considered due to mutations that affect efficacy, and demonstrate that the antiviral compounds molnupiravir and S-217622 are effective against Omicron BA.1 variants.Therapeutic monoclonal antibodies (COV2-2196/COV2-2130) inhibited the replication of SARS-CoV-2 Omicron BA.1 but not BA.1.1 variants in the lungs of Syrian hamsters. Antivirals (molnupiravir and S-217622) were effective against BA.1 in hamsters.
Author Takashita, Emi
Uraki, Ryuta
Watanabe, Shinji
Ujie, Michiko
Yasuhara, Atsuhiro
Iwatsuki-Horimoto, Kiyoko
Yamayoshi, Seiya
Fujisaki, Seiichiro
Kiso, Maki
Furusawa, Yuri
Kawaoka, Yoshihiro
Sakai-Tagawa, Yuko
Imai, Masaki
Ito, Mutsumi
Hasegawa, Hideki
Author_xml – sequence: 1
  givenname: Ryuta
  orcidid: 0000-0003-0890-1922
  surname: Uraki
  fullname: Uraki, Ryuta
  organization: Division of Virology, Institute of Medical Science, University of Tokyo, The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute
– sequence: 2
  givenname: Maki
  surname: Kiso
  fullname: Kiso, Maki
  organization: Division of Virology, Institute of Medical Science, University of Tokyo
– sequence: 3
  givenname: Masaki
  orcidid: 0000-0001-6988-1975
  surname: Imai
  fullname: Imai, Masaki
  organization: Division of Virology, Institute of Medical Science, University of Tokyo, The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute
– sequence: 4
  givenname: Seiya
  orcidid: 0000-0001-7768-5157
  surname: Yamayoshi
  fullname: Yamayoshi, Seiya
  organization: Division of Virology, Institute of Medical Science, University of Tokyo, The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute
– sequence: 5
  givenname: Mutsumi
  surname: Ito
  fullname: Ito, Mutsumi
  organization: Division of Virology, Institute of Medical Science, University of Tokyo
– sequence: 6
  givenname: Seiichiro
  surname: Fujisaki
  fullname: Fujisaki, Seiichiro
  organization: Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama
– sequence: 7
  givenname: Emi
  orcidid: 0000-0002-9064-4699
  surname: Takashita
  fullname: Takashita, Emi
  organization: Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama
– sequence: 8
  givenname: Michiko
  surname: Ujie
  fullname: Ujie, Michiko
  organization: Division of Virology, Institute of Medical Science, University of Tokyo, The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute
– sequence: 9
  givenname: Yuri
  surname: Furusawa
  fullname: Furusawa, Yuri
  organization: Division of Virology, Institute of Medical Science, University of Tokyo, The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute
– sequence: 10
  givenname: Atsuhiro
  surname: Yasuhara
  fullname: Yasuhara, Atsuhiro
  organization: Division of Virology, Institute of Medical Science, University of Tokyo
– sequence: 11
  givenname: Kiyoko
  orcidid: 0000-0002-8266-020X
  surname: Iwatsuki-Horimoto
  fullname: Iwatsuki-Horimoto, Kiyoko
  organization: Division of Virology, Institute of Medical Science, University of Tokyo
– sequence: 12
  givenname: Yuko
  surname: Sakai-Tagawa
  fullname: Sakai-Tagawa, Yuko
  organization: Division of Virology, Institute of Medical Science, University of Tokyo
– sequence: 13
  givenname: Shinji
  surname: Watanabe
  fullname: Watanabe, Shinji
  organization: Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama
– sequence: 14
  givenname: Hideki
  surname: Hasegawa
  fullname: Hasegawa, Hideki
  organization: Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama
– sequence: 15
  givenname: Yoshihiro
  orcidid: 0000-0001-5061-8296
  surname: Kawaoka
  fullname: Kawaoka, Yoshihiro
  email: yoshihiro.kawaoka@wisc.edu
  organization: Division of Virology, Institute of Medical Science, University of Tokyo, The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35705860$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1rHDEMhk1JadI0f6CHYuilF6f-tnvcLv2CQKCb9mo8HjtxmLG3tiew_77ebEJLDjlJQs8rJL2vwVHKyQPwluBzgpn-WDkRkiNMKcKEKIz4C3BCsdBIUCWP_suPwVmttxhjIqmUWr4Cx0yo3pX4BOSrG1_s1i8tOuhDiM66HcwBzjllN-VkJ2hTi0Meo689He_Lu1js1MtrG1NtcLP6uUHr_BtReDlHV3KCn1fnBMYEN7sSbYI3dq7Nl_oGvAxd6c8e4in49fXL1fo7urj89mO9ukCOa9GQdAO2WFGiXbDcCzUOY7A4SI_JIDmRTgxaac2dlora0bkgsGYuMOsUoSM7BR8Oc7cl_1l8bWaO1flpssnnpRoqlRKKYcE7-v4JepuX0g_fU580k4wT2ql3D9QyzH402xJnW3bm8ZUd0Aegn19r8cG42GyLObVi42QINnvjzME4040z98aZ_Qb0ifRx-rMidhDVDqdrX_6t_YzqL_2IqWQ
CitedBy_id crossref_primary_10_1016_j_ebiom_2024_105439
crossref_primary_10_1371_journal_ppat_1012600
crossref_primary_10_1016_j_ebiom_2023_104950
crossref_primary_10_1128_aac_00697_22
crossref_primary_10_3390_ph15081021
crossref_primary_10_1080_10717544_2022_2163003
crossref_primary_10_1016_j_apsb_2023_02_010
crossref_primary_10_3390_v15112151
crossref_primary_10_1021_acscentsci_2c01203
crossref_primary_10_1080_14656566_2022_2146493
crossref_primary_10_3390_v15061300
crossref_primary_10_1016_j_clim_2024_109902
crossref_primary_10_1016_j_cmpb_2024_108543
crossref_primary_10_3390_ijms24032264
crossref_primary_10_1002_iid3_1262
crossref_primary_10_3389_fcell_2023_1238027
crossref_primary_10_3389_fmicb_2023_1132501
crossref_primary_10_1016_j_chembiol_2024_03_008
crossref_primary_10_1097_MD_0000000000033024
crossref_primary_10_1016_j_isci_2024_110729
crossref_primary_10_1016_j_heliyon_2024_e30222
crossref_primary_10_1016_j_jcyt_2022_10_003
Cites_doi 10.1107/S0907444908007877
10.1038/s41564-021-00972-2
10.1073/pnas.2002589117
10.1038/s41586-020-2342-5
10.1038/s41586-022-04474-x
10.1038/s41467-021-24435-8
10.1086/500465
10.1038/s41541-020-00279-z
10.1056/NEJMc2119407
10.1126/science.abd0826
10.1038/s41586-021-03925-1
10.1016/j.cell.2021.05.005
10.1038/s41586-022-04441-6
10.4049/jimmunol.169.9.5171
10.1086/516358
10.1016/j.cell.2021.02.026
10.1038/s41586-021-03720-y
10.1016/S0002-9343(97)00007-7
10.1038/s41586-021-03312-w
10.1016/j.cell.2020.02.058
10.1038/s41586-020-2852-1
10.1038/s41467-021-26096-z
10.1038/s41586-020-2548-6
10.1126/science.abd0831
10.1038/s41564-019-0401-1
10.1002/cpim.116
10.1371/journal.ppat.1010340
10.1016/j.eclinm.2021.100734
10.1038/nbt.1601
10.1073/pnas.2009799117
10.1038/s41594-021-00651-0
10.5501/wjv.v5.i2.85
10.1016/j.cell.2021.12.033
10.1038/s41586-021-04388-0
10.1038/s41586-022-04399-5
10.1038/s41586-022-04856-1
10.1038/s41586-021-04389-z
10.1038/s41586-021-04386-2
10.1038/s41586-021-04385-3
10.1073/pnas.2106535118
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Nature Limited 2022
2022. The Author(s), under exclusive licence to Springer Nature Limited.
The Author(s), under exclusive licence to Springer Nature Limited 2022.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Nature Limited 2022
– notice: 2022. The Author(s), under exclusive licence to Springer Nature Limited.
– notice: The Author(s), under exclusive licence to Springer Nature Limited 2022.
DBID AAYXX
CITATION
NPM
8FE
8FH
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PHGZM
PHGZT
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1038/s41564-022-01170-4
DatabaseName CrossRef
PubMed
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
ProQuest Central Student
SciTech Premium Collection
Biological Sciences
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest Central Student
ProQuest Biological Science Collection
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2058-5276
EndPage 1258
ExternalDocumentID 35705860
10_1038_s41564_022_01170_4
Genre Journal Article
GrantInformation_xml – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
– fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP21fk0108615; JP20fk0108472; JP20nk0101632; JP21wm0125002; JP20fk0108412
  funderid: https://doi.org/10.13039/100009619
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: HHSN272201400008C; 75N93021C00014
  funderid: https://doi.org/10.13039/100000060
– fundername: NIAID NIH HHS
  grantid: HHSN272201400008C
– fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP21wm0125002
– fundername: NIAID NIH HHS
  grantid: 75N93021C00014
– fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP20fk0108412
– fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP20fk0108472
– fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP20nk0101632
– fundername: Japan Agency for Medical Research and Development (AMED)
  grantid: JP21fk0108615
GroupedDBID 0R~
53G
8FE
8FH
AAEEF
AAHBH
AARCD
AAYZH
AAZLF
ABJNI
ABLJU
ACBWK
ACGFS
ADBBV
AFBBN
AFKRA
AFSHS
AFWHJ
AHSBF
AIBTJ
ALFFA
ALMA_UNASSIGNED_HOLDINGS
ARMCB
AXYYD
BBNVY
BENPR
BHPHI
BKKNO
CCPQU
EBS
EJD
FSGXE
FZEXT
HCIFZ
HZ~
LK8
M7P
NNMJJ
O9-
ODYON
R9-
RNT
SHXYY
SIXXV
SNYQT
SOJ
TAOOD
TBHMF
TDRGL
TSG
AAYXX
ABFSG
ACSTC
AEZWR
AFANA
AFHIU
AHWEU
AIXLP
ATHPR
CITATION
PHGZM
PHGZT
NPM
AZQEC
DWQXO
GNUQQ
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c485t-6cb0a07218cfa4e57dbdfa0f6e01b6416c5b87884c8672adccf5083cf3ac712d3
IEDL.DBID BENPR
ISSN 2058-5276
IngestDate Fri Jul 11 13:09:12 EDT 2025
Sat Aug 23 12:25:26 EDT 2025
Wed Feb 19 02:26:19 EST 2025
Thu Apr 24 23:03:35 EDT 2025
Tue Jul 01 00:55:57 EDT 2025
Fri Feb 21 02:38:21 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License 2022. The Author(s), under exclusive licence to Springer Nature Limited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c485t-6cb0a07218cfa4e57dbdfa0f6e01b6416c5b87884c8672adccf5083cf3ac712d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-9064-4699
0000-0001-7768-5157
0000-0001-5061-8296
0000-0003-0890-1922
0000-0001-6988-1975
0000-0002-8266-020X
OpenAccessLink https://www.nature.com/articles/s41564-022-01170-4.pdf
PMID 35705860
PQID 2698363412
PQPubID 2069616
PageCount 7
ParticipantIDs proquest_miscellaneous_2677573054
proquest_journals_2698363412
pubmed_primary_35705860
crossref_citationtrail_10_1038_s41564_022_01170_4
crossref_primary_10_1038_s41564_022_01170_4
springer_journals_10_1038_s41564_022_01170_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-08-01
PublicationDateYYYYMMDD 2022-08-01
PublicationDate_xml – month: 08
  year: 2022
  text: 2022-08-01
  day: 01
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature microbiology
PublicationTitleAbbrev Nat Microbiol
PublicationTitleAlternate Nat Microbiol
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Meng (CR31) 2022; 603
Englund (CR24) 1998; 26
Tomris (CR33) 2022; 18
Chan (CR9) 2020; 71
Lempp (CR28) 2021; 598
Barnes (CR18) 2020; 588
Winkler (CR29) 2021; 184
Corti, Purcell, Snell, Veesler (CR13) 2021; 184
Ferren (CR32) 2021; 12
CR35
Matsuyama (CR34) 2020; 117
Kabinger (CR27) 2021; 28
Ramakrishnan (CR40) 2016; 5
Hsieh (CR38) 2020; 369
Takashita (CR14) 2022; 386
Chen (CR17) 2021; 596
Halfmann (CR30) 2022; 603
Imai (CR7) 2020; 117
CR2
Brocato (CR26) 2021; 6
Walls (CR1) 2020; 181
CR4
CR3
CR6
Baum (CR15) 2020; 369
CR5
Vanderheiden (CR39) 2020; 131
Sia (CR8) 2020; 583
Ison, Gubareva, Atmar, Treanor, Hayden (CR25) 2006; 193
Wahl (CR22) 2021; 591
Dong (CR19) 2021; 6
Greaney (CR20) 2021; 12
CR21
Zost (CR16) 2020; 584
CR41
Oganesyan, Gao, Shirinian, Wu, Dall’Acqua (CR12) 2008; 64
Yamayoshi (CR37) 2021; 32
Bowden (CR23) 1997; 102
Yasuhara (CR36) 2019; 4
Zalevsky (CR10) 2010; 28
Dall’Acqua (CR11) 2002; 169
SF Sia (1170_CR8) 2020; 583
CL Hsieh (1170_CR38) 2020; 369
ES Winkler (1170_CR29) 2021; 184
MG Ison (1170_CR25) 2006; 193
M Ferren (1170_CR32) 2021; 12
1170_CR3
A Wahl (1170_CR22) 2021; 591
RL Brocato (1170_CR26) 2021; 6
1170_CR4
A Vanderheiden (1170_CR39) 2020; 131
1170_CR2
FA Lempp (1170_CR28) 2021; 598
V Oganesyan (1170_CR12) 2008; 64
M Imai (1170_CR7) 2020; 117
WF Dall’Acqua (1170_CR11) 2002; 169
MA Ramakrishnan (1170_CR40) 2016; 5
1170_CR21
J Zalevsky (1170_CR10) 2010; 28
F Kabinger (1170_CR27) 2021; 28
D Corti (1170_CR13) 2021; 184
1170_CR41
PJ Halfmann (1170_CR30) 2022; 603
RE Chen (1170_CR17) 2021; 596
S Yamayoshi (1170_CR37) 2021; 32
JA Englund (1170_CR24) 1998; 26
JF Chan (1170_CR9) 2020; 71
RA Bowden (1170_CR23) 1997; 102
A Yasuhara (1170_CR36) 2019; 4
A Baum (1170_CR15) 2020; 369
B Meng (1170_CR31) 2022; 603
S Matsuyama (1170_CR34) 2020; 117
I Tomris (1170_CR33) 2022; 18
E Takashita (1170_CR14) 2022; 386
AJ Greaney (1170_CR20) 2021; 12
1170_CR5
1170_CR6
CO Barnes (1170_CR18) 2020; 588
1170_CR35
AC Walls (1170_CR1) 2020; 181
J Dong (1170_CR19) 2021; 6
SJ Zost (1170_CR16) 2020; 584
References_xml – volume: 64
  start-page: 700
  year: 2008
  end-page: 704
  ident: CR12
  article-title: Structural characterization of a human Fc fragment engineered for lack of effector functions
  publication-title: Acta Crystallogr. D
  doi: 10.1107/S0907444908007877
– volume: 6
  start-page: 1233
  year: 2021
  end-page: 1244
  ident: CR19
  article-title: Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-021-00972-2
– volume: 117
  start-page: 7001
  year: 2020
  end-page: 7003
  ident: CR34
  article-title: Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2002589117
– volume: 583
  start-page: 834
  year: 2020
  end-page: 838
  ident: CR8
  article-title: Pathogenesis and transmission of SARS-CoV-2 in golden hamsters
  publication-title: Nature
  doi: 10.1038/s41586-020-2342-5
– ident: CR4
– ident: CR2
– volume: 71
  start-page: 2428
  year: 2020
  end-page: 2446
  ident: CR9
  article-title: Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility
  publication-title: Clin. Infect. Dis.
– volume: 603
  start-page: 706
  year: 2022
  end-page: 714
  ident: CR31
  article-title: Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
  publication-title: Nature
  doi: 10.1038/s41586-022-04474-x
– volume: 12
  year: 2021
  ident: CR20
  article-title: Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-24435-8
– volume: 193
  start-page: 760
  year: 2006
  end-page: 764
  ident: CR25
  article-title: Recovery of drug-resistant influenza virus from immunocompromised patients: a case series
  publication-title: J. Infect. Dis.
  doi: 10.1086/500465
– ident: CR35
– ident: CR6
– volume: 6
  year: 2021
  ident: CR26
  article-title: Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-020-00279-z
– volume: 386
  start-page: 995
  year: 2022
  end-page: 998
  ident: CR14
  article-title: Efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2119407
– volume: 369
  start-page: 1501
  year: 2020
  end-page: 1505
  ident: CR38
  article-title: Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
  publication-title: Science
  doi: 10.1126/science.abd0826
– volume: 598
  start-page: 342
  year: 2021
  end-page: 347
  ident: CR28
  article-title: Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
  publication-title: Nature
  doi: 10.1038/s41586-021-03925-1
– volume: 184
  start-page: 3086
  year: 2021
  end-page: 3108
  ident: CR13
  article-title: Tackling COVID-19 with neutralizing monoclonal antibodies
  publication-title: Cell
  doi: 10.1016/j.cell.2021.05.005
– volume: 603
  start-page: 687
  year: 2022
  end-page: 692
  ident: CR30
  article-title: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
  publication-title: Nature
  doi: 10.1038/s41586-022-04441-6
– volume: 169
  start-page: 5171
  year: 2002
  end-page: 5180
  ident: CR11
  article-title: Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.169.9.5171
– ident: CR21
– volume: 26
  start-page: 1418
  year: 1998
  end-page: 1424
  ident: CR24
  article-title: Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults
  publication-title: Clin. Infect. Dis.
  doi: 10.1086/516358
– volume: 184
  start-page: 1804
  year: 2021
  end-page: 1820.e16
  ident: CR29
  article-title: Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
  publication-title: Cell
  doi: 10.1016/j.cell.2021.02.026
– volume: 596
  start-page: 103
  year: 2021
  end-page: 108
  ident: CR17
  article-title: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
  publication-title: Nature
  doi: 10.1038/s41586-021-03720-y
– volume: 102
  start-page: 27
  year: 1997
  end-page: 30
  ident: CR23
  article-title: Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience
  publication-title: Am. J. Med
  doi: 10.1016/S0002-9343(97)00007-7
– ident: CR3
– volume: 591
  start-page: 451
  year: 2021
  end-page: 457
  ident: CR22
  article-title: SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
  publication-title: Nature
  doi: 10.1038/s41586-021-03312-w
– volume: 181
  start-page: 281
  year: 2020
  end-page: 292.e6
  ident: CR1
  article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.058
– volume: 588
  start-page: 682
  year: 2020
  end-page: 687
  ident: CR18
  article-title: SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
  publication-title: Nature
  doi: 10.1038/s41586-020-2852-1
– volume: 12
  year: 2021
  ident: CR32
  article-title: Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-26096-z
– volume: 584
  start-page: 443
  year: 2020
  end-page: 449
  ident: CR16
  article-title: Potently neutralizing and protective human antibodies against SARS-CoV-2
  publication-title: Nature
  doi: 10.1038/s41586-020-2548-6
– volume: 369
  start-page: 1014
  year: 2020
  end-page: 1018
  ident: CR15
  article-title: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
  publication-title: Science
  doi: 10.1126/science.abd0831
– volume: 4
  start-page: 1024
  year: 2019
  end-page: 1034
  ident: CR36
  article-title: Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-019-0401-1
– volume: 131
  start-page: e116
  year: 2020
  ident: CR39
  article-title: Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies
  publication-title: Curr. Protoc. Immunol.
  doi: 10.1002/cpim.116
– volume: 18
  start-page: e1010340
  year: 2022
  ident: CR33
  article-title: Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1010340
– ident: CR5
– volume: 32
  start-page: 100734
  year: 2021
  ident: CR37
  article-title: Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.100734
– volume: 28
  start-page: 157
  year: 2010
  end-page: 159
  ident: CR10
  article-title: Enhanced antibody half-life improves in vivo activity
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1601
– volume: 117
  start-page: 16587
  year: 2020
  end-page: 16595
  ident: CR7
  article-title: Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2009799117
– ident: CR41
– volume: 28
  start-page: 740
  year: 2021
  end-page: 746
  ident: CR27
  article-title: Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/s41594-021-00651-0
– volume: 5
  start-page: 85
  year: 2016
  end-page: 86
  ident: CR40
  article-title: Determination of 50% endpoint titer using a simple formula
  publication-title: World J. Virol.
  doi: 10.5501/wjv.v5.i2.85
– volume: 169
  start-page: 5171
  year: 2002
  ident: 1170_CR11
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.169.9.5171
– ident: 1170_CR21
  doi: 10.1016/j.cell.2021.12.033
– volume: 26
  start-page: 1418
  year: 1998
  ident: 1170_CR24
  publication-title: Clin. Infect. Dis.
  doi: 10.1086/516358
– ident: 1170_CR6
  doi: 10.1038/s41586-021-04388-0
– volume: 6
  start-page: 1233
  year: 2021
  ident: 1170_CR19
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-021-00972-2
– volume: 584
  start-page: 443
  year: 2020
  ident: 1170_CR16
  publication-title: Nature
  doi: 10.1038/s41586-020-2548-6
– volume: 32
  start-page: 100734
  year: 2021
  ident: 1170_CR37
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.100734
– volume: 4
  start-page: 1024
  year: 2019
  ident: 1170_CR36
  publication-title: Nat. Microbiol.
  doi: 10.1038/s41564-019-0401-1
– volume: 583
  start-page: 834
  year: 2020
  ident: 1170_CR8
  publication-title: Nature
  doi: 10.1038/s41586-020-2342-5
– volume: 28
  start-page: 740
  year: 2021
  ident: 1170_CR27
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/s41594-021-00651-0
– volume: 5
  start-page: 85
  year: 2016
  ident: 1170_CR40
  publication-title: World J. Virol.
  doi: 10.5501/wjv.v5.i2.85
– ident: 1170_CR5
  doi: 10.1038/s41586-022-04399-5
– volume: 12
  year: 2021
  ident: 1170_CR32
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-26096-z
– ident: 1170_CR41
  doi: 10.1038/s41586-022-04856-1
– volume: 117
  start-page: 16587
  year: 2020
  ident: 1170_CR7
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2009799117
– volume: 193
  start-page: 760
  year: 2006
  ident: 1170_CR25
  publication-title: J. Infect. Dis.
  doi: 10.1086/500465
– volume: 603
  start-page: 687
  year: 2022
  ident: 1170_CR30
  publication-title: Nature
  doi: 10.1038/s41586-022-04441-6
– volume: 18
  start-page: e1010340
  year: 2022
  ident: 1170_CR33
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1010340
– volume: 598
  start-page: 342
  year: 2021
  ident: 1170_CR28
  publication-title: Nature
  doi: 10.1038/s41586-021-03925-1
– volume: 6
  year: 2021
  ident: 1170_CR26
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-020-00279-z
– ident: 1170_CR2
  doi: 10.1038/s41586-021-04389-z
– volume: 184
  start-page: 1804
  year: 2021
  ident: 1170_CR29
  publication-title: Cell
  doi: 10.1016/j.cell.2021.02.026
– volume: 64
  start-page: 700
  year: 2008
  ident: 1170_CR12
  publication-title: Acta Crystallogr. D
  doi: 10.1107/S0907444908007877
– volume: 71
  start-page: 2428
  year: 2020
  ident: 1170_CR9
  publication-title: Clin. Infect. Dis.
– volume: 12
  year: 2021
  ident: 1170_CR20
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-24435-8
– volume: 596
  start-page: 103
  year: 2021
  ident: 1170_CR17
  publication-title: Nature
  doi: 10.1038/s41586-021-03720-y
– volume: 28
  start-page: 157
  year: 2010
  ident: 1170_CR10
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1601
– volume: 117
  start-page: 7001
  year: 2020
  ident: 1170_CR34
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.2002589117
– volume: 181
  start-page: 281
  year: 2020
  ident: 1170_CR1
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.058
– volume: 184
  start-page: 3086
  year: 2021
  ident: 1170_CR13
  publication-title: Cell
  doi: 10.1016/j.cell.2021.05.005
– ident: 1170_CR3
  doi: 10.1038/s41586-021-04386-2
– ident: 1170_CR4
  doi: 10.1038/s41586-021-04385-3
– volume: 369
  start-page: 1014
  year: 2020
  ident: 1170_CR15
  publication-title: Science
  doi: 10.1126/science.abd0831
– volume: 369
  start-page: 1501
  year: 2020
  ident: 1170_CR38
  publication-title: Science
  doi: 10.1126/science.abd0826
– volume: 131
  start-page: e116
  year: 2020
  ident: 1170_CR39
  publication-title: Curr. Protoc. Immunol.
  doi: 10.1002/cpim.116
– volume: 102
  start-page: 27
  year: 1997
  ident: 1170_CR23
  publication-title: Am. J. Med
  doi: 10.1016/S0002-9343(97)00007-7
– volume: 591
  start-page: 451
  year: 2021
  ident: 1170_CR22
  publication-title: Nature
  doi: 10.1038/s41586-021-03312-w
– ident: 1170_CR35
  doi: 10.1073/pnas.2106535118
– volume: 386
  start-page: 995
  year: 2022
  ident: 1170_CR14
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2119407
– volume: 588
  start-page: 682
  year: 2020
  ident: 1170_CR18
  publication-title: Nature
  doi: 10.1038/s41586-020-2852-1
– volume: 603
  start-page: 706
  year: 2022
  ident: 1170_CR31
  publication-title: Nature
  doi: 10.1038/s41586-022-04474-x
SSID ssj0001626686
Score 2.328583
Snippet The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host’s protective immune response. Here...
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major antigen stimulating the host's protective immune response. Here...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1252
SubjectTerms 631/326/596/1296
631/326/596/4130
64
82/1
Antiviral agents
Biomedical and Life Sciences
Coronaviruses
DNA-directed RNA polymerase
Immune response
Infectious Diseases
Life Sciences
Medical Microbiology
Microbiology
Monoclonal antibodies
Parasitology
Proteinase inhibitors
Replication
RNA polymerase
RNA-directed RNA polymerase
Rodents
Severe acute respiratory syndrome coronavirus 2
Spike protein
Virology
Title Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters
URI https://link.springer.com/article/10.1038/s41564-022-01170-4
https://www.ncbi.nlm.nih.gov/pubmed/35705860
https://www.proquest.com/docview/2698363412
https://www.proquest.com/docview/2677573054
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swELe2VpP2Mm1jGx0MeRJvm8FJ_NWnqUVUaA8FUUC8RY5jQ6WSsLU89L_nLnFbIQRvseIv3Z3PP_vOd4TsG5HavjR9ZoOCA4rWnBX9pGQBH1kq43gSGgfZsTq5FH-v5XW8cJtHt8qVTmwUdVk7vCM_TFXfZAp0bvrn_h_DrFFoXY0pNN6SLqhgYzqkOzwen51vblkAryuj4msZnpnDOZ5YBEMndt5kXRFPd6RnMPOZibTZeUYfyYcIGemg5fEn8sZXn8m7NonkcovUF5snVNRjRAjrlrQOFGZcuxkibQrkmxY1OgzCZ9kU0bl3BsUbOwWESCeD8wk7qq9YSk_v0EmvosPBQUKnFZ0sQUgremvvMKjC_Au5HB1fHJ2wmEaBOWHkgilXcIth0IwLVnipy6IMlgfleVIoAGROFgZOwsIZpVNbOhcwRrwLmXU6ScvsK-lUdeW3CRU6WAwR6I3lwgJUcK5UMvNaOC58KnokWZEydzHGOKa6mOWNrTszeUv-HMifN-TPoc2vdZv7NsLGq7V3VxzK42qb5xvZ6JGf69-wTtD4YStfP2AdrSWoMwldfGs5ux4uk5pLo3iP_F6xetP5y3P5_vpcdsj7tBEz9BbcJZ3F_wf_AxDMotgj3cFoOBzvRXF9BJnC7O8
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BqdELwg7hQGGAmewMxxHNt9QKgbmzo2Clo7tLfgOPZWqUsG7YT6U3wj5-TSCk3sbW-xYjvWueUcnxshr40UtpeYHrNBgYGiNWdZL8pZwCRLZRyPQhUgO1SDI_n5ODleI3_aXBgMq2xlYiWo89LhHfmmUD0TK5C54uP5T4Zdo9C72rbQqMli3y9-g8k2-7D3CfD7RojdnfH2gDVdBZiTJpkz5TJusSqYccFKn-g8y4PlQXkeZQr0E5dkBgxD6YzSwubOBSyZ7kJsnY5EHsO-N8i6jBUXHbK-tTP8dri61QH7QBnVZOfw2GzO0EKSDIPmedXlRf77B7yk1l5yyVZ_ut275E6jotJ-TVP3yJov7pObddPKxQNSjlcpW9RjBQrrFrQMFCBUuilq9hTQNclKDFCEx7waYjDxFIYndgIaKR31D0dsu_zOBP16hkGBBd3qv4_opKCjBTBFQU_tGRZxmD0kR9cC4EekU5SFf0Ko1MFiSUJvLJcWVBPncpXEXkvHpReyS6IWlKlrappja41pWvnWY5PW4E8B_GkF_hTWvF2uOa8relw5e6PFUNpw9yxd0WKXvFq-Br5EZ4stfHmBc7ROQHwmsMXjGrPLz8WJ5olRvEvetahebf7_szy9-iwvya3B-MtBerA33H9GbouK5DBScYN05r8u_HPQnubZi4ZkKflx3VzyFyLMKZc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+efficacy+of+monoclonal+antibodies+and+antivirals+against+SARS-CoV-2+Omicron+BA.1+in+Syrian+hamsters&rft.jtitle=Nature+microbiology&rft.au=Uraki%2C+Ryuta&rft.au=Kiso%2C+Maki&rft.au=Imai%2C+Masaki&rft.au=Yamayoshi%2C+Seiya&rft.date=2022-08-01&rft.issn=2058-5276&rft.eissn=2058-5276&rft.volume=7&rft.issue=8&rft.spage=1252&rft_id=info:doi/10.1038%2Fs41564-022-01170-4&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2058-5276&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2058-5276&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2058-5276&client=summon